팬젠
Financials
Valuation Metrics
팬젠's Market Cap is ₩676B. At end of 2025 it was ₩757B. Ranked #1519 of 2,436 in KR market (top 62%), #877 of 1,649 on KOSDAQ (top 53%), #169 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 72%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.57B KRW | KR#1,519/2,436 Sec#169/234 |
| Revenue | 13.71B KRW | KR#2,231/2,436 Sec#167/234 |
| Net Income | 2.06B KRW | KR#1,349/2,436 Sec#96/234 |
| Total Assets | 33.46B KRW | KR#2,305/2,436 Sec#217/234 |
| Net Assets | 30.67B KRW | KR#2,159/2,436 Sec#191/234 |
| Employees | 75 | KR#1,821/2,436 Sec#155/234 |
| Value | ||
| P/E | 32.72x | KR#1,276/2,436 Sec#80/234 |
| P/B | 2.20x | KR#1,992/2,436 Sec#149/234 |
| PEG | 16.78x | KR#841/2,436 Sec#57/234 |
| P/S | 4.93x | KR#2,140/2,436 Sec#140/234 |
| EV/EBITDA | 50.38x | KR#1,347/2,436 Sec#90/234 |
| FCF Yield | -0.55% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 6.73% | KR#821/2,436 Sec#60/234 |
| ROA | 6.17% | KR#509/2,436 Sec#38/234 |
| Op. Margin | 9.39% | KR#529/2,436 Sec#50/234 |
| Revenue Growth | 8.43% | KR#990/2,436 Sec#89/234 |
| Earnings Growth | 1.95% | KR#884/2,436 Sec#60/234 |
| Financial Health | ||
| Debt Ratio | 9.07% | KR#9/2,436 Sec#3/234 |
| Total Debt | 1.00B KRW | KR#1,958/2,436 Sec#190/234 |
| FCF | -373.0M KRW | KR#1,249/2,436 Sec#94/234 |
| Cash | 3.70B KRW | KR#2,093/2,436 Sec#193/234 |
| Current Ratio | 8.67x | KR#128/2,436 Sec#32/234 |
| Net Debt/EBITDA | -2.10x | KR#289/2,436 Sec#16/234 |
| Performance | ||
| 1Y Return | -18.30% | KR#1,217/2,436 Sec#98/234 |
| 1M Return | 4.60% | KR#504/2,436 Sec#41/234 |
| From 52W High | -41.25% | KR#812/2,436 Sec#56/234 |
| 1Y MDD | -41.01% | KR#552/2,436 Sec#42/234 |
| Trading | ||
| Volume | 8,111 shares | KR#2,171/2,436 Sec#216/234 |
| Foreign Own. | 7.41% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 154 KRW | KR#1,282/2,436 Sec#89/234 |
| BPS | 2,273 KRW | KR#1,966/2,436 Sec#162/234 |
Company Info
PanGen, established in 2010 as a spin-off, was listed on KOSDAQ as a technology growth company in 2016. The company provides biosimilar EPO drug production and sales, biopharmaceutical contract manufacturing, and development technology transfer services, leveraging its PanGen CHO-TECH™ technology and GMP facilities. Its EPO drugs are sold in Asia and Saudi Arabia, and it has completed clinical Phase 3 sample production for Hemophilia A treatment, along with non-clinical trials for macular degeneration treatment and anti-cancer adjuvants. PanGen is headquartered in Suwon-si, Gyeonggi-do.